Company Directory

High-sensitivity lateral flow diagnostics for point-of-care testing

SwiftDx is a Cambridge-based diagnostics company developing a next generation of high-sensitivity lateral flow assays using proprietary eAMP (enhanced Amplification) and DNA detection technologies. Its platform enables detection of targets undetectable by conventional lateral flow tests, without requiring specialist equipment or laboratory facilities. The company's first commercial product is a rapid mycoplasma contamination detection kit for cell culture applications. Further products in development target HIV, dengue fever, hepatitis C, and prostate cancer.

Human biospecimen and disease-state plasma supplier

Logical Biological is a UK supplier of human biological materials including disease-state and normal-donor serum, plasma, swabs, tissues, PBMCs, and biofluids to IVD manufacturers and life science researchers worldwide. The company sources specimens through a global network of donor centres and blood banks across five continents, and provides customised materials including bulk engineered disease-state plasma, with capabilities in protein purification and sample processing. Customers include diagnostic test developers and IVD control manufacturers.

GCP-accredited oncology molecular diagnostics for clinical trials and research

The Cancer Molecular Diagnostics Laboratory is an ISO 15189-accredited molecular diagnostics facility within the University of Cambridge Department of Oncology, jointly funded by CRUK and NIHR. Operating to GCP and GCLP standards, it provides next-generation sequencing, circulating tumour DNA analysis, liquid biopsy workflows, and digital PCR services for oncology clinical trials and translational research. Services are available to clinical trials, independent research groups, and biotechnology companies as a site, central laboratory, and contract researcher.

AI-powered infrared diagnostic test for breast cancer recurrence risk

Digistain is a biotechnology company developing MHRA-cleared diagnostic technology for predicting breast cancer recurrence risk. The platform uses infrared spectrometry to generate spectroscopic signatures from tumour biopsy tissue, with AI analysis producing a personalised prognostic score indicating the likelihood of disease recurrence over ten years. The technology is designed as a faster and lower-cost alternative to transcriptomic profiling methods, enabling patient stratification for adjuvant chemotherapy decisions.

In vitro diagnostic reagents, test kits and analysers for clinical laboratories

Fortress Diagnostics is a Northern Ireland-based manufacturer of in vitro diagnostic products, supplying clinical chemistry reagents, immunoassays, haematology reagents, haemostasis consumables, serology test kits, quality controls and calibrators, and diagnostic instrumentation to hospitals, blood banks, and research institutions across more than 100 countries. Operating from an ISO 13485-accredited facility at Antrim Technology Park, the company distributes through an established global network spanning five continents.

AI-powered rare disease case finding for primary care

Mendelian is a digital health software company developing AI-driven tools to support the earlier diagnosis of rare diseases in primary care. Its core product is a Class 1 regulated medical device that analyses electronic health records to identify patients whose symptom profiles are consistent with published diagnostic criteria for hundreds of rare conditions. The platform integrates with NHS clinical workflows and is used by GPs and primary care networks across the UK.

Automated molecular diagnostics for HLA typing and blood group testing

MC Diagnostics is a specialist molecular diagnostics company developing and manufacturing automated multiplexed assay solutions for clinical and reference laboratories. The company's proprietary platform delivers proven diagnostic assays for HLA typing and blood group testing, supported by integrated image capture and interpretation software. MC Diagnostics also distributes transplant and transfusion diagnostics products across the UK, Ireland, and Australia. The facility operates to ISO 13485 standard with CE-marked product lines.

Non-invasive oral cancer screening using genomics and cell-free DNA

Wisdom Bioscience is a biotechnology company developing a non-invasive oral cancer screening platform that integrates next-generation sequencing and cell-free DNA analysis with saliva-based sample collection. The platform is designed to enable early detection of oral cancer through routine dental appointments, addressing a disease area where outcomes are strongly dependent on stage at diagnosis. The company is progressing through clinical validation ahead of commercial launch.

AI-powered cancer biomarker profiling from tissue images

Panakeia is an AI diagnostics company developing software that predicts molecular biomarker status directly from standard H&E-stained tissue images. Its CE-marked and UKCA-certified breast cancer product reports ER, PR, and HER2 status in minutes, reducing the need for conventional laboratory testing. The platform extends across more than 30 cancer types for research and clinical trial applications, supporting pharma partners in biomarker validation and patient stratification.

Diagnostic reagents, instruments and quality controls for clinical and research laboratories

Randox Laboratories is a global manufacturer of in vitro diagnostic reagents, clinical chemistry analysers, quality control materials, and biochip array technology for laboratory medicine. Products serve clinical, research, molecular, forensic toxicology, food safety, and veterinary laboratory markets across more than 145 countries. Randox manufactures approximately 15% of all worldwide cholesterol tests and 10% of all clinical chemistry tests, and reinvests up to 25% of annual turnover in research and development.

AI platform predicting patient response to cancer immunotherapy

Curenetics is a medical technology company developing AI-powered tools to predict cancer patient responses to immunotherapy before treatment begins. Its platform integrates multi-omic genomic data, imaging profiles and clinical information to identify biomarkers of treatment efficacy and toxicity. The company also offers AI-driven clinical trial matching for cancer patients. Founded by practicing NHS oncologist Dr Sola Adeleke, Curenetics collaborates with the University of Pittsburgh, Queen Mary University of London and multiple NHS trusts.

Solutions for genomics, diagnostics and precision medicine

QIAGEN is a global provider of sample preparation, molecular diagnostics, and genomics solutions for pharmaceutical, clinical, and research applications. Its UK headquarters at Citylabs 2.0, Manchester serves as the company's global centre of excellence for precision medicine and companion diagnostics, co-developing diagnostic tests with more than 25 pharmaceutical partners. The Manchester site maintains close partnerships with the University of Manchester and Manchester University NHS Foundation Trust.